2026-01-20 - Analysis Report
# Financial Report: Abbott Laboratories (ABT)

## Company Overview
Abbott Laboratories is a multinational American medical device and healthcare company.

## Return Rate Comparison
| Ticker | Cumulative Return (%) | Difference (cumulative return) |
|--------|----------------------|-------------------------------|
| ABT    | 32.54%               |                              |
| VOO    | 93.30%               | -60.80% (divergence)          |

## Alpha, Beta Analysis
| Date Range | CAGR | MDD | Alpha | Beta | Cap (B) |
|------------|------|------|-------|-------|----------|
| 2016-2018  | 32.0% | 14.5% | 28.0% | 1.1   | 125.9B   |
| 2017-2019  | 41.0% | 14.5% | 24.0% | 1.0   | 151.2B   |
| 2018-2020  | -1.0% | 16.8% | -22.0% | 0.9   | 190.6B   |
| 2019-2021  | 42.0% | 16.8% | -2.0%  | 0.8   | 244.9B   |
| 2020-2022  | -20.0% | 28.8% | -18.0% | 0.8   | 191.1B   |
| 2021-2023  | -22.0% | 28.8% | -23.0% | 0.7   | 191.6B   |
| 2022-2024  | -31.0% | 24.3% | -50.0% | 0.7   | 196.9B   |
| 2023-2025  | 10.0%  | 16.0% | -52.0% | 0.3   | 218.1B   |

## Recent Stock Price Fluctuations
- 5-day SMA: $123.85
- 20-day SMA: $125.12
- 60-day SMA: $125.91
- Close: $121.76
- Last-market: -1.43% (-$1.77)

## RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence
- RSI: 39.06
- PPO: -0.24
- Market Risk Indicator (MRI): 0.80
- Hybrid Signal: Buy
- Risk Level: Medium
- Recent (20 days) relative divergence change: -2.00 (worsening)
- 7-day Rank change: 116 (rank up)
- 7-day Dynamic Expected Return change: -18.70 (worsening)
- Expected Return: -1605.30%

## Recent News & Significant Events
- [2026-01-19] Abbott Laboratories: Q4 Earnings On The Horizon (NYSE:ABT)
- [2026-01-19] Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings?
- [2026-01-06] PBH vs. ABT: Which Stock Is the Better Value Option?
- [2026-01-19] ABT.SW Abbott Laboratories (SIX) at CHF100.00 pre-earnings: watch 22 Jan for guidance
- [2026-01-16] Fund Update: New $84.6M $ABT stock position opened by Compagnie Lombard Odier SCmA
- [2026-01-18] Abbott Laboratories (ABT) Positioned to Benefit as Healthcare Sector Enters Recovery Phase

## Analyst Opinions
- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.71 (~Buy)
  - Opinions: 25
  - Target Price (avg/high/low): 144.75 / 169.00 / 122.00

## Recent Earnings Analysis
| Date | EPS | Revenue |
|------|------|----------|
| 2025-10-29 | 0.94 | $11.37 B |
| 2025-07-30 | 1.02 | $11.14 B |
| 2025-04-30 | 0.76 | $10.36 B |
| 2024-10-31 | 0.94 | $10.63 B |
| 2025-10-29 | 0.94 | $10.63 B |

## Financial Information
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

## Comprehensive Analysis
Based on the provided data, Abbott Laboratories (ABT) has seen varied performance across different date ranges, with certain periods experiencing significant losses. The recent stock price fluctuations and RSI, PPO index indicators suggest a potential decline. Analyst opinions are generally positive, with a consensus of "Buy" and a mean rating of 1.71. However, the company's recent earnings and financial information, including revenue and profitability, have shown mixed results. Overall, the comprehensive analysis indicates a cautious approach may be warranted.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.